Citations

Showing 10 of 108104 citations.

20+ Years and alive with primary myelofibrosis: Phenotypic signature of very long‐lived patients
Penna, Domenico , Finke, Christy M. , Vallapureddy, Rangit, Hanson, Curtis A. , Pardanani, Animesh , Gangat, Naseema , Tefferi, Ayalew , Lasho, Terra L. , Vallapureddy, Rangit R, Gangat, Naseema , Tefferi, Ayalew , Ketterling, Rhett P.

Mayo Clinic

American Journal of Hematology | December 5, 2018 | Volume: 94 | Issue: 3 | Pages: 286-290

10.1002/ajh.25351 | PMID 30516867 Get It

AbstractIn the last decade, several prognostic models for primary myelofibrosis (PMF) have been introduced and shown to be effective in predicting overall survival. The main objective for this study was to identify clinical and genetic markers of very long (20+ years) survival in PMF. A total of 1282 patients with PMF were considered (median age 65 years, range 19‐92; 63% males); 26 (2%) patients (median age 51 years, range 28‐71; 38% males) survived their disease for at least 20 years (long‐lived patients) and 626 (49%) patients (median age 68 years, range 27‐92; 66% males) died within 5 years of their diagnosis (short‐lived patients). Multivariable logistic regression analysis identified 7 variables that were associated with survival beyond 20 years: age ≤ 70 years (P = .002); female sex (P = .03); hemoglobin level ≥ 10 g/dL for women and ≥ 11 g/dL for men (P = .03), leukocyte count ≤25 × 109/L (P = .009), platelet count ≥100 × 109/L (P = .002), circulating blasts <2% (P = .03) and absence of constitutional symptoms (P = .04). Five‐year mortality was independently predicted by high‐molecular risk mutations (P < .001); unfavorable or very high risk karyotype (P < .001); absence of type 1/like CALR mutation (P < .001); age > 70 years (P < .001); constitutional symptoms (P < .001); hemoglobin level < 10 g/dL for women and < 11 g/dL for men (P < .001); leukocyte count >25 × 109/L (P = .004); and circulating blasts ≥2% (P = .001). This study suggests that genetic risk factors in PMF are associated with early mortality while survival beyond 20 years could be predicted by easily accessible clinical variables, including age, sex, blood counts, and symptoms.
Response letter‐to‐the editor entitled “Transvenous lead extraction, only once or repeatable?”
Cha, Yong‐Mei , Birgersdotter‐Green, Ulrika

Mayo Clinic

Pacing and Clinical Electrophysiology | December 5, 2018 | Volume: 42 | Issue: 2 | Pages: 297-297

10.1111/pace.13561 | PMID 30516285 Get It

Fabrication of composite microfluidic devices for local control of oxygen tension in cell cultures
Gao, Yandong , Revzin, Alexander , Stybayeva, Gulnaz

Mayo Clinic

Lab on a Chip | December 5, 2018 | Volume: 19 | Issue: 2 | Pages: 306-315

10.1039/c8lc00825f | PMID 30547179 Get It

We developed a microfabrication strategy that integrated two materials with different gas permeability in a single microfluidic chip to enable local control of oxygen tension for cell cultures.
Role of systemic high‐dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990‐2018
Castellino, Alessia , Pulido, José S. , Johnston, Patrick B. , Ristow, Kay M., Inwards, David J. , Macon, William R. , Micallef, Ivana N. , King, Rebecca L. , Salomão, Diva R. , Nowakowski, Grzegorz S. , Micallef, Ivana N M, Witzig, T.E. , Bennani, N. Nora , Witzig, Thomas E. , Habermann, Thomas M.

Mayo Clinic

American Journal of Hematology | December 5, 2018 | Volume: 94 | Issue: 3 | Pages: 291-298

10.1002/ajh.25350 | PMID 30516868 Get It

Abstract Vitreoretinal lymphoma (VRL) management remains a challenge. We present 72 patients with VRL, diagnosed at Mayo Clinic between 1990‐2018. Three nondiffuse large B‐cell lymphoma (DLBCL) histology cases were excluded. Among 69 DLBCL, 33 patients had primary VRL (PVRL), 18 concurrent intraocular and central nervous system (CNS) or systemic disease and 18 secondary VRL. Patients received intraocular chemotherapy (intraocular injections of rituximab or metothrexate or steroids or in combination), radiotherapy, systemic or combined systemic plus intraocular treatment in 9, 10, 35, and 15 cases, respectively. Among primary and concurrent VRL, median failure free survival (FFS), CNS relapse‐free survival (CNS‐RFS) and overall survival (OS) were: 1.8, 4.9, and 4.1 years, respectively; among PVRL, median FFS, CNS‐RFS, and OS were: 2.6 year, Not Reached and 9.3 year, respectively. No CNS relapse occurred beyond 4 years in PVRL. Median OS for patients diagnosed between 1990 and 1999 vs between 2000 and 2018 was 1.5 vs 9.4 years, respectively ( P = .0002). OS was significantly higher in PVRL, as compared with concurrent VRL ( P = .04). Previous immunosuppression and poor performance status were predictive of worse outcome. In PVRL, a combined systemic and intraocular therapy showed higher FFS ( P = .002) and CNS‐RFS ( P = .003), but no differences in OS. Among 18 secondary VRL, at a median follow‐up of 1.1 year after vitreoretinal relapse, median FFS and OS were 0.3 and 1.3 years. An improvement in survival of VRL has been observed over the decades. PVRL should undergo combined systemic and intraocular chemotherapy to prevent CNS progression.
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myeloma
Binder, Moritz , Rajkumar, S. Vincent , Lacy, Martha Q. , Gertz, Morie A. , Hwa, Yi L. , Fonder, Amie , Hobbs, Miriam, Hayman, Suzanne R. , Zeldenrust, Steven R., Lust, John A., Russell, Stephen J. , Kapoor, Prashant , Kourelis, Taxiarchis , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Buadi, Francis K. , Leung, Nelson , Go, Ronald S , Gonsalves, Wilson , Kourelis, Taxiarchis , Warsame, Rahma , Rajkumar, S Vincent , Gertz, Morie A , Binder, Moritz , Russell, Stephen J , Dispenzieri, Angela , Leung, Nelson , Go, Ronald S. , Gonsalves, Wilson I.

Mayo Clinic

American Journal of Hematology | December 5, 2018 | Volume: 94 | Issue: 3 | Pages: 306-311

10.1002/ajh.25365 | PMID 30516847 Get It

Abstract Peripheral blood biomarkers of tumor microenvironment and immune surveillance are independent prognostic factors in multiple myeloma. The timing and prognostic impact of immune reconstitution has been studied after autologous hematopoietic stem cell transplantation, less is known about its significance in newly diagnosed multiple myeloma. We studied absolute lymphocyte (ALC) and absolute monocyte (AMC) counts at the time of treatment initiation and 1 month thereafter in 771 newly diagnosed patients. Two hundred and thirty‐four patients (31%) had evidence of immune dysregulation at baseline (abnormal biomarkers). Eighty‐seven of these patients (37%) recovered normal biomarkers at 1 month (early immune reconstitution). The absence of immune dysregulation at baseline (compared to the presence thereof) was associated with better overall survival (HR 0.77, 95% CI 0.61‐0.97, P = 0.025, n = 771). The absence of immune dysregulation at 1 month (compared to the persistence or development thereof) was associated with better overall survival (HR 0.63, 95% CI 0.50‐0.80, P < 0.001, n = 771). Early immune reconstitution (compared to the persistence or development of immune dysregulation) was associated with better overall survival (HR 0.62, 95% CI 0.43‐0.92, P = 0.016, n = 771). Cytogenetic high‐risk disease was negatively, and treatment with immunomodulators positively, associated with early immune reconstitution. The presence or development of immune dysregulation in newly diagnosed multiple myeloma is an independent risk factor. The favorable impact of early immune reconstitution suggests immune dysregulation to be a potentially modifiable risk factor that may be exploited for therapeutic benefit.
Kidney Discard Rates in the United States During American Transplant Congress Meetings
Elhamahmi, Dina Abdelwahab, Chaly, Thomas, Wei, Guo , Hall, Isaac E. , Abdelwahab Elhamahmi, Dina, Chaly, Thomas

Mayo Clinic

Transplantation Direct | December 5, 2018 | Volume: 5 | Issue: 1 | Pages: e412

10.1097/txd.0000000000000849 | PMID 30656210 Get It

Background Deceased-donor kidney discard rates vary by region, but it is unknown whether discard rates and transplant outcomes vary during the American Transplant Congress (ATC) each year. Methods Using national registry data, we determined rates of kidney discard, delayed graft function, graft failure, and mortality from December 31, 1999, through December 30, 2015, during ATC dates and compared these rates with those on the same days of the week during the 2 weeks before and after the ATC (non-ATC). We used multivariable regression to determine associations between ATC and these outcomes. Results From 7902 donors (1575 ATC; 6327 non-ATC), 12 588 recipients received kidney transplants (2455 ATC; 10 133 non-ATC), and 2666 kidneys were discarded (582 ATC; 2084 non-ATC). Kidneys were more often discarded during ATC (19% vs 17%, P = 0.006; adjusted odds ratio, 1.21; 95% confidence interval, 1.05-1.40). There were no significant differences in donor, transplant, or recipient characteristics by ATC/non-ATC dates or by ATC/non-ATC transplant dates for delayed graft function, graft failure, or mortality. Conclusions On the basis of a 21% increased odds of discard, the ATC itself may result in 5 additional kidney discards during this important conference every year, which suggests the need for innovative staffing or other logistic solutions during these planned meetings.
Delivering the Diagnosis of Sex Chromosome Aneuploidy: Experiences and Preferences of Parents and Individuals
Jaramillo, Carolina, Nyquist, Christina , Riggan, Kirsten A. , Egginton, Jason S. , Allyse, Megan , Egginton, Jason, Phelan, Sean, Allyse, Megan A , Phelan, Sean M. , Riggan, Kirsten A

Mayo Clinic

Clinical Pediatrics | December 5, 2018 | Volume: 58 | Issue: 3 | Pages: 336-342

10.1177/0009922818817310 | PMID 30516062 Get It

Increased prenatal diagnoses of sex chromosome aneuploidies (SCAs) amid limited knowledge of their prognoses heighten the need to understand how families contend with the implications of an SCA. To explore the experiences of parents and individuals who received a genetic diagnosis of an SCA (excluding Turner syndrome), we conducted semistructured qualitative telephone interviews with 43 participants affected by these conditions. Parents (n = 35) and individuals (n = 8) expressed almost unanimous interest in more optimistic portrayals of their condition from their providers, even when the prognosis is uncertain. While some participants reported success in receiving accurate information from their provider and identifying supportive resources, numerous families received outdated or misleading information about their condition and lacked direction in accessing follow-up care and support. Parents desire greater coordination of their child’s medical care and access to care that approaches an SCA holistically. Opportunities remain to improve the diagnosis and care of individuals with SCAs.
CORR Insights®: Chemotherapy Curtails Bone Formation From Compliant Compression Fixation of Distal Femoral Endoprostheses
Beauchamp, C.P. , Beauchamp, Christopher P.

Mayo Clinic

Clinical Orthopaedics & Related Research | December 5, 2018 | Volume: 477 | Issue: 1 | Pages: 217-218

10.1097/corr.0000000000000556 | PMID 30516654 Get It

Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma
Jin, Zhaohui , Holubek, Marie, Sukov, William R. , Sattler, Christopher A., Wiktor, Anne E., Jenkins, Robert B. , Wu, Tsung‐Teh, Yoon, Harry H. , Jin, Zhaohui

Mayo Clinic

American Journal of Clinical Oncology | December 5, 2018 | Volume: 42 | Issue: 2 | Pages: 190-195

10.1097/coc.0000000000000495 | PMID 30516569 Get It

Background: Our purpose was to evaluate the prognostic impact of pathologically confirmed esophageal adenosquamous carcinoma (ASC) and its association with HER2 status and clinicopathologic characteristics. Methods: Among 796 patients with esophageal or gastroesophageal junction adenocarcinoma who underwent curative resection, surgical pathology reports were reviewed, and suspected ASC was confirmed utilizing p63 and CK5/6 immunostaining. HER2 status was determined using immunohistochemistry and fluorescence in situ hybridization. Cox models were used to assess the impact of ASC on disease-specific survival and overall survival. Results: Overall, 2.0% (16/796) of patients had esophageal ASC, mostly demonstrating a close intermingling of squamous and adenocarcinoma cells within the same tumor. The percentage of squamous versus adenocarcinoma cells in the primary was generally recapitulated in nodal metastases, and intrapatient internodal heterogeneity was uncommon. Patients with esophageal ASC were statistically significantly more likely to be female (vs. male), have normal (vs. excess) body mass index, and harbor HER2-negative (vs. positive) tumors, as compared with patients with adenocarcinoma only. No ASC tumor was HER2-positive as compared with 16% of adenocarcinoma only tumors (P=0.018). Compared with patients with adenocarcinoma only, those with ASC demonstrated profoundly worse disease-specific survival (5-year event-free rate, 34% vs. 6%; multivariate hazard ratio, 2.87 [95% confidence interval, 1.59-4.76]; P=0.0010) and overall survival (P=0.0027) that was independent of known prognostic factors and HER2 status. Conclusion: ASC identifies a rare aggressive HER2-negative subgroup of esophageal/gastroesophageal junction adenocarcinoma.